TheStreet's co-portfolio manager Jim Cramer says DexCom is a poster child for what is both right and wrong with today's market. DexCom, which makes a device to monitor glucose remotely with no finger pricking, is a disruptive technology that is taking the Type One diabetes world by storm. Cramer says the stock has taken a hit when investors stopped paying attention to cash flow positive stocks and started focusing on earnings per share instead. DexCom has added expenses because they are hiring more salespeople, but Cramer expects the device maker to be cash flow positive in 2015. Cramer believes the stock will turnaround next year.

More from Video

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

Amazon Prime Tops 100 Million Members and 4 Other Stories You Must Know Thursday

Amazon Prime Tops 100 Million Members and 4 Other Stories You Must Know Thursday

AAP Exclusive: Cramer on Why They Sold Broadcom Shares

AAP Exclusive: Cramer on Why They Sold Broadcom Shares

AAP Exclusive: Cramer's Trust Has Made $2.5M in Charitable Distributions

AAP Exclusive: Cramer's Trust Has Made $2.5M in Charitable Distributions

Jim Cramer: I Don't Want to Panic About Snap

Jim Cramer: I Don't Want to Panic About Snap